Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. The company develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. It also develops JADE201 and JADE-003, which are in preclinical development stage. The company has a collaboration agreement with Paragon Therapeutics, Inc. Jade Biosciences, Inc. was founded in 2024 and is headquartered in Waltham, Massachusetts. Show more
Location: Building 23, Waltham, MA, 02453, United States | Website: https://jadebiosciences.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
264.9M
52 Wk Range
$6.57 - $105.00
Previous Close
$8.12
Open
$8.04
Volume
41,111
Day Range
$7.69 - $8.31
Enterprise Value
44.78M
Cash
220.9M
Avg Qtr Burn
-11.31M
Insider Ownership
0.04%
Institutional Own.
99.05%
Qtr Updated
06/30/25
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
JADE101 Details Immunoglobulin A nephropathy (IgAN) | Phase 1 Data readout |